GlassScriptPhysician profile
Orest J Kozicky
NPI 1861496481
$2,342.06
in general payments reported to CMS, 2019-2025
19 companies · $31.21 in 2025
The $31.21 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,304 · 2020: $695 · 2021: $311 · 2025: $31.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $31.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $31.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $510.89 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $360.93 | 2019-2021 | |
| Janssen Biotech, INC. | $280.38 | 2019-2021 | |
| Pfizer INC. | $245.20 | 2019-2020 | |
| Ucb, INC. | $183.38 | 2019 | |
| Redhill Biopharma INC. | $177.71 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $131.07 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.42 | 2020 | |
| Gilead Sciences, INC. | $55.92 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $52.20 | 2020 | |
| Merck Sharp & Dohme LLC | $47.53 | 2019-2020 | |
| Boston Scientific Corporation | $40.83 | 2019 | |
| Concordia Pharmaceuticals INC. | $34.70 | 2019 | |
| Alfasigma USA, INC. | $34.28 | 2020 | |
| Allergan, INC. | $33.89 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $31.21 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Nestle Healthcare Nutrition INC. | $23.83 | 2021 | |
| Intercept Pharmaceuticals, INC. | $22.72 | 2021 | |
| Braintree Laboratories, INC. | $17.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orest Kozicky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.